RNA, U6 small nuclear 125, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-125P profile across patient tissues and cancer cell-line models. RNU6-125P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RNU6-125P is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, RNU6-125P RNA expression shows 15,755 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, HNSC, and UVM as cancer lineages where RNU6-125P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-125P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-125P survival associations across molecular data types. RNU6-125P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-125P RNA expression–survival associations across cancer types. High RNU6-125P expression shows unfavorable associations in UCEC, MESO, LUSC, LGG and LIHC, but favorable associations in HNSC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for RNU6-125P RNA expression.
This table summarizes RNU6-125P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-125P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-125P shows lower tumor expression in COAD and LUSC and higher tumor expression in HNSC, KIRC, LIHC and BLCA. The HNSC box plot shows higher RNU6-125P RNA expression in tumor versus normal tissue (log2 FC = +0.513, t-test p = .003).
This table shows molecular features associated with RNU6-125P in patient tissues and cancer cell lines. In patient samples, RNU6-125P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
